To address the promising clinical findings of TNF-α inhibitors in T1D and the limited transition of DMTs to pivotal clinical trials, Breakthrough T1D convened a panel of key opinion leaders (KOLs) in the field. The gene discussed is TNF; the disease is type 1 diabetes mellitus.